Latest Tax Incentives News

Cardiex Limited reported a $3 million cash outflow in Q4 2025 but is banking on cost reductions and new product sales to improve its financial footing. The company also secured $6.5 million through a capital raise to bolster its runway.

Papyrus Australia has made significant strides in Q2 2025, launching its Rapid Prototyping and R&D Facility and successfully trialling new banana fibre-based products, while deepening academic partnerships.

Marquee Resources has progressed its Mt Clement antimony-gold project with Phase 1 drilling completed and assay results pending, alongside a $596,000 capital raise and a key executive appointment.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Activeport Group Ltd reported a strong Q4 FY25 with significant revenue growth in software and Network as a Service segments, underpinned by new contracts with leading telecom providers and improved cash flow management.

ABx Group Limited reports promising rare earth exploration results in Tasmania, steady progress on its ALCORE fluorine recycling pilot plant, and advancing bauxite mining projects in Queensland and Tasmania, while managing funding challenges.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

Decidr AI Industries reported an 82% revenue jump in its AI platform during Q4 FY25, launched AI Mentors with The Growth Faculty, and divested its 13Seeds business to sharpen focus on AI innovation.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

Golden Mile Resources has completed its first Reverse Circulation drilling campaign at the Pearl Copper Project in Arizona, revealing significant copper, lead, zinc, and silver mineralisation. Meanwhile, drilling continues at its Leonora Gold JV with assay results pending.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.